ArticleInternational journal of chronic obstructive pulmonary disease2019
Prevalence of cardiac comorbidities, and their underdetection and contribution to exertional symptoms in COPD: results from the COSYCONET cohort.
Article in International journal of chronic obstructive pulmonary disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01245933 (Impact of Systemic Manifestations/Comorbidities on Clinical State, Prognosis and Utilisation of Health Care Resources in Patients With COPD), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of Systemic Manifestations/Comorbidities on Clinical State, Prognosis and Utilisation of Health Care Resources in Patients With COPD
Who cites it
24 citing papers in PubMed, 52 citations in OpenAlex.
- Absence of Adverse Effects of Tiotropium/Olodaterol Compared with the Monocomponents on Long-Term Heart Rate and Blood Pressure in Patients with Moderate-to-Very-Severe COPD.International journal of chronic obstructive pulmonary disease · 2020Trial
- Cardiovascular Outcomes Among Patients with COPD Prescribed with LABA or LAMA: A Real-World Territory Wide Study.Advances in therapy · 2025Article
- Prediction of Multimorbidity Network Evolution in Middle-Aged and Elderly Population Based on CE-GCN.Interdisciplinary sciences, computational life sciences · 2025Review
- Association of Obesity with Symptoms and Quality of Life in COPD: Results from COSYCONET.International journal of chronic obstructive pulmonary disease · 2025Observational
- Biological pathways and mechanisms linking COPD and cardiovascular disease.Therapeutic advances in chronic disease · 2025Review
- Skin Markers of Premature Ageing in Patients with COPD: Results Form COSYCONET.Journal of clinical medicine · 2024Article
- Midregional proatrial naturetic peptide (MRproANP) and copeptin (COPAVP) as predictors of all-cause mortality in recently diagnosed mild to moderate COPD-results from COSYCONET.Respiratory research · 2024Article
- The Diagnosis and Treatment of COPD and Its Comorbidities.Deutsches Arzteblatt international · 2023Review
- Cardiovascular Diseases in COPD: From Diagnosis and Prevalence to Therapy.Life (Basel, Switzerland) · 2023Review
- Gender-specific differences in COPD symptoms and their impact for the diagnosis of cardiac comorbidities.Clinical research in cardiology : official journal of the German Cardiac Society · 2023Article
- [What have we learned from the German COPD cohort COSYCONET and where do we go from here?]Pneumologie (Stuttgart, Germany) · 2023Article
- Characteristics of Current Smokers versus Former Smokers with COPD and Their Associations with Smoking Cessation Within 4.5 Years: Results from COSYCONET.International journal of chronic obstructive pulmonary disease · 2023Article
- Cardiovascular predictors of mortality and exacerbations in patients with COPD.Scientific reports · 2022Article
- Characteristics of patients referred to Canary Island pneumology outpatient services for chronic obstructive pulmonary disease: the EPOCan study.BMC research notes · 2022Observational
- Disease Progression and Age as Factors Underlying Multimorbidity in Patients with COPD: Results from COSYCONET.International journal of chronic obstructive pulmonary disease · 2022Article
- A pilot investigation of e-cigarette use and smoking behaviour among patients with chronic airway disease or respiratory symptoms.The clinical respiratory journal · 2022Article
- Effects of Dynamic Hyperinflation on Left Ventricular Diastolic Function in Healthy Subjects - A Randomized Controlled Crossover Trial.Frontiers in medicine · 2021Article
- Integrating Comorbidities and Phenotype-Based Medicine in Patient-Centered Medicine in COPD.Journal of clinical medicine · 2020Review
- Prediction of air trapping or pulmonary hyperinflation by forced spirometry in COPD patients: results from COSYCONET.ERJ open research · 2020Article
- Impact of Education on COPD Severity and All-Cause Mortality in Lifetime Never-Smokers and Longtime Ex-Smokers: Results of the COSYCONET Cohort.International journal of chronic obstructive pulmonary disease · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A substantial prevalence of cardiovascular disease is known for COPD, but detection of its presence, relationship to functional findings and contribution to symptoms remains challenging. The present analysis focusses on the cardiovascular contribution to COPD symptoms and their relationship to the patients' diagnostic status, medication and echocardiographic findings. Methods: Patients from the COPD cohort COSYCONET with data on lung function, including FEV Results: A total of 1591 patients (GOLD 0-4: n=230/126/614/498/123) fulfilled the inclusion criteria. Ischemic heart disease, myocardial infarction or heart failure were reported in 289 patients (18.2%); 860 patients (54%) received at least one cardiovascular medication, with more than one in many patients. LVEF<50% or LVEDD>56 mm was found in 204 patients (12.8%), of whom 74 (36.3%) had neither a cardiovascular history nor medication. Among 948 patients (59.6%) without isolated hypertension, there were 21/55 (38.2%) patients with LVEF<50% and 47/88 (53.4%) with LVEDD>56 mm, who lacked both a cardiac diagnosis and medication. LVEDD and LVEF were linked to medical history; LVEDD was dependent on RV/TLC and LVEF on FEV Conclusion: A remarkable proportion of patients with suspicious echocardiographic findings were undiagnosed and untreated, implying an increased risk for an unfavorable prognosis. Cardiac size and function were dependent on lung function and only partially linked to cardiovascular history. Although the contribution of LV size to COPD symptoms was small compared to lung function, it was detectable irrespective of all other influencing factors. However, only the mMRC and SGRQ activity component were found to be suitable for this purpose.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.